You are here: Industry Insights > OA

News List

TrialSpark Licenses Sprifermin from Merck KGaA, Forms High Line Bio contractpharma
January 10, 2022
Sprifermin promotes cartilage growth, and could be a potential disease modifying treatment for osteoarthritis.
TissueTech Receives FDA Clearance for TTAX03 Study to Treat Facet Joint Osteoarthritis Pain americanpharmaceuticalreview
March 12, 2021
Amniox Medical announced its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from OA.
FDA Accepts Regulatory Submission for Tanezumab americanpharmaceuticalreview
March 04, 2020
Pfizer and Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC) ...
Risk for Cardiovascular Deaths Increased With Hip, Knee OA drugs
August 06, 2019
The risk for cardiovascular deaths is increased among patients with knee and hip osteoarthritis...
Tanezumab Improves Scores for Pain, Function in Osteoarthritis drugs
July 04, 2019
Tanezumab Improves Scores for Pain, Function in Osteoarthritis.
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis worldpharmanews
April 23, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
Hip Preservation Appropriateness Guidelines May Be Limited drugs
February 15, 2019
The American Academy of Orthopaedic Surgeons (AAOS) hip preservation surgery appropriateness classification system is driven almost entirely by age and radiographic hip osteoarthritis (OA) evaluation...